For the quarter ending 2025-09-30, GLSI had $681,877 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,151,845 | -7,283,640 |
| Amortization | 0 | 1,779 |
| Stock-based compensation | 1,544,214 | 3,088,428 |
| Accounts payable | -187,590 | 118,940 |
| Unreimbursed expenses related party (accrued) | 123,982 | 6,936 |
| Net cash used in operating activities | -2,671,239 | -4,067,557 |
| Sale of common stock via private placement, net of costs | - | 0 |
| Sale of common stock via atm program, net of costs | 3,208,116 | 3,100,668 |
| Net proceeds from exercise of remaining underwriter warrants | 145,000 | - |
| Net cash provided by (used in) financing activities | 3,353,116 | 3,100,668 |
| Net increase (decrease) in cash | 681,877 | -966,889 |
| Cash and cash equivalents at beginning of period | 4,091,990 | - |
| Cash and cash equivalents at end of period | 3,806,978 | - |
Greenwich LifeSciences, Inc. (GLSI)
Greenwich LifeSciences, Inc. (GLSI)